Rotigotine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB05271 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | attention deficit-hyperactivity disorder | KG + DL |
| 2 | schizophrenia | KG + DL |
| 3 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 4 | faciodigitogenital syndrome | KG + DL |
| 5 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 6 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 7 | myopia X-linked | KG + DL |
| 8 | atypical glycine encephalopathy | KG + DL |
| 9 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 10 | myopia 26, X-linked, female-limited | KG + DL |
| 11 | syndromic myopia | KG + DL |
| 12 | hydranencephaly (disease) | KG + DL |
| 13 | attention deficit hyperactivity disorder, inattentive type | KG + DL |
| 14 | chondromyxoid fibroma | KG + DL |
| 15 | specific developmental disorder | KG + DL |
| 16 | trichotillomania | KG + DL |
| 17 | PLA2G6-associated neurodegeneration | KG + DL |
| 18 | variably protease-sensitive prionopathy | KG + DL |
| 19 | paralysis agitans, juvenile, of Hunt | KG + DL |
| 20 | Rasmussen subacute encephalitis | KG + DL |
| 21 | mixed anxiety and depressive disorder | KG + DL |
| 22 | major affective disorder | KG + DL |
| 23 | transaldolase deficiency | KG + DL |
| 24 | myelitis | KG + DL |
| 25 | lethal infantile mitochondrial myopathy | KG + DL |
| 26 | tic disorder | KG + DL |
| 27 | transient tic disorder | KG + DL |
| 28 | Tourette syndrome | KG + DL |
| 29 | Lewy body dementia | KG + DL |
| 30 | fructose-1,6-bisphosphatase deficiency | KG + DL |
| 31 | progressive supranuclear palsy-corticobasal syndrome | KG + DL |
| 32 | distal 17p13.3 microdeletion syndrome | KG + DL |
| 33 | postencephalitic Parkinson disease | KG + DL |
| 34 | familial congenital mirror movements | KG + DL |
| 35 | communication disorder | KG + DL |
| 36 | X-linked intellectual disability-ataxia-apraxia syndrome | KG + DL |
| 37 | developmental disorder of mental health | KG + DL |
| 38 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | KG + DL |
| 39 | X-linked intellectual disability-cerebellar hypoplasia syndrome | KG + DL |
| 40 | stereotypic movement disorder | KG + DL |
| 41 | fetal nicotine spectrum disorder | KG + DL |
| 42 | CLCN4-related X-linked intellectual disability syndrome | KG + DL |
| 43 | manic bipolar affective disorder | KG + DL |
| 44 | multiple system atrophy, parkinsonian type | KG + DL |
| 45 | X-linked intellectual disability-spastic quadriparesis syndrome | KG + DL |
| 46 | X-linked cerebral-cerebellar-coloboma syndrome syndrome | KG + DL |
| 47 | syndromic X-linked intellectual disability Chudley-Schwartz type | KG + DL |
| 48 | autosomal dominant striatal neurodegeneration type 1 | KG + DL |
| 49 | intellectual disability, X-linked, syndromic | KG + DL |
| 50 | lissencephaly type 1 due to doublecortin gene mutation | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.